Stocks

Strengths: Robust revenue growth and strong market presence in the homebuilding sector. Weaknesses: Increased construction costs and legal contingencies impacting profitability. Opportunities: Expansion into new markets and potential for increased demand in affordable housing. Threats: Rising interest rates and economic fluctuations posing challenges. Warning! …

Participants Alicia A. Charity; SVP of IR; Ameriprise Financial, Inc. James M. Cracchiolo; Chairman & CEO; Ameriprise Financial, Inc. Walter S. Berman; Executive VP, CFO & Chief Risk Officer; Ameriprise Financial, Inc. Alexander Blostein; Lead Capital Markets Analyst; Goldman Sachs Group, Inc., Research Division …

Norsk Hydro Hydro’s adjusted EBITDA for the first quarter of 2024 was NOK 5,411 million, down from NOK 7,525 million for the same quarter last year. Lower aluminium sales prices, Extrusions volumes and recycling margins, and higher fixed costs negatively impacted results, partly offset …

IMCD N.V. Photo_IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma Photographed from left to right:•Cristina Marti, Director API Sales and Strategy, IMCD Group•Gianluca Galimberti, General Manager, Cobapharma•Tess Hendriks, Legal Counsel M&A, IMCD Group•Fenna van Zanten, Director M&A, IMCD Group•Jose Alcover, Managing …

F. Hoffmann-La Roche Ltd Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of …

Key Insights GEA Group's Annual General Meeting to take place on 30th of April Salary of €1.44m is part of CEO Stefan Klebert's total remuneration The total compensation is 136% higher than the average for the industry Over the past three years, GEA Group's …

Novartis Pharma AG There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the …